Table of Contents
Advances in the treatment of chronic hepatitis C: Update to the Committee
Treating chronic hepatitis C 10 years of progress
Advancements in the treatment of chronic hepatitis C Participant Introduction
PPT Slide
Treatment chronic hepatitis C Information provided to the committee
The PEG-Intron molecule
Intron A 3MU TIW Sustained virologic response by patient weight
PPT Slide
PEG-Intron monotherapy virologic response
PEG-Intron monotherapy virologic response
PEG-Intron monotherapy Factors Associated with Sustained Virologic Response*
PEG-Intron dose selection
PEG-Intron plus Rebetol
Demographics
Disease Characteristics
Sustained Virologic Response
Sustained Virologic Response
PPT Slide
Effect of Rebetol dose mg/kg on virologic response (Logistic regression analysis)
All genotypes Sustained virologic response Controlling for Rebetol dose (mg/kg)
HCV-1 Sustained virologic response Controlling for Rebetol dose (mg/kg)
HCV-2/3 Sustained virologic response Controlling for Rebetol dose (mg/kg)
Sustained virologic response Controlling for Rebetol dose (mg/kg)
Relapse Controlling for Rebetol dose and genotype
PPT Slide
PEG-Intron/Rebetol Safety
PPT Slide
Discontinuations and dose modifications due to adverse events
Dose modification ɮ% difference between groups
PPT Slide
Adverse hematologic effects Hemoglobin
Safety Summary
PPT Slide
Dr. J. McHutchison
The Decision to Treat Hepatitis C
Weighing the Risks and Benefits
Decision to Treat
Decision to Treat Hepatitis C
How can we achieve the greatest benefit whilst diminishing the risk?
|